Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M

Alaunos Therapeutics, Inc.

Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.
Authorized shares of common stock increased from 34,666,667 to 50,000,000.
Five directors elected: Curtis Hogue Jr., Robert Hofmeister, Robert Postma, Jaime Vieser, Holger Weis.
Advisory vote on executive compensation passed with 1,851,846 for and 1,032,789 against.
Ratification of RSM US LLP as independent auditor for FY 2024 approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.